New dosing strategies for an old antibiotic: Pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1381-1388

  Rao, Gauri G ^a   Ly, Neang S ^a   Haas, Curtis E ^b   Garonzik, Samira ^a,c   Forrest, Alan ^a   Bulitta, Jurgen B ^a,d   Kelchlin, Pamela A ^a   Holden, Patricia N ^a   Nation, Roger L ^d   Li, Jian ^d   Tsujia, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DENSITY; DISEASE SIMULATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; IN VITRO STUDY; INOCULATION; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; COLISTIN; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MODELS, BIOLOGICAL; PSEUDOMONAS INFECTIONS;

EID: 84896860491     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00327-13     Document Type: Article

References (47)

1. Paterson DL, Lipman J. 2007. Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit. Care Med. 35:1789-1791. http://dx.doi.org/10.1097/01.CCM.0000269352.39174.A4. (Pubitemid 46985895)
2. Lim T-P, Lee W, Tan T-Y, Sasikala S, Teo J, Hsu L-Y, Tan T-T, Syahidah N, Kwa AL. 2011. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 6:e28177. http://dx.doi.org/10.1371/journal.pone.0028177.
3. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668. http://dx.doi.org/10.1086/499819. (Pubitemid 43271379)
4. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47):pii=19045. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19045.
5. Rossolini GM, Mantengoli E. 2005. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11(Suppl 4):17-32. http://dx.doi.org/10.1111/j.1469-0691.2005.01161.x. (Pubitemid 40946169)
6. Falagas ME, Kasiakou SK, Saravolatz LD. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. http://dx.doi.org/10.1086/429323. (Pubitemid 40570245)
7. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
8. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M, Pavleas J, Skiada A, Daikos GL, Rigas K, Mega A, Archondoulis N, Vernikos P, Salatas K, Thomopoulos G. 2006. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU Int. J. Antimicrob. Agents 28: 366-369. http://dx.doi.org/10.1016/j. ijantimicag.2006.07.008. (Pubitemid 44403003)
9. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465. http://dx.doi.org/10.1128/CMR.00006-08.
10. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339. http://dx.doi.org/10.1378/chest.10-0463.
11. De Pascale G, Sandroni C, Antonelli M. 2011. Colistin use in critically ill patients. Chest 139:234. http://dx.doi.org/10.1378/chest.10-2031.
12. Roberts J, Roberts M, Semark A, Udy A, Kirkpatrick C, Paterson D, Roberts M, Kruger P, Lipman J. 2011. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/ pharmacodynamics in sepsis and trauma patients.BMC Anesthesiol. 11:3. http://dx.doi.org/10.1186/ 1471-2253-11-3.
13. Varghese JM, Roberts JA, Lipman J. 2010. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr. Opin. Anesthesiol. 23:472-478. http://dx.doi.org/10.1097/ACO.0b013e328339ef0a.
14. Michalopoulos A, Falagas ME. 2008. Colistin and polymyxin B in critical care. Crit. Care Clin. 24:377-391. http://dx.doi.org/10.1016/j.ccc.2007.12.003. (Pubitemid 351400615)
15. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30: 1279-1291. http://dx.doi.org/10.1592/phco.30.12.1279.
16. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. http://dx.doi.org/10.1093/jac/dkg468. (Pubitemid 38008420)
17. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gramnegative bacteria. Antimicrob. Agents Chemother. 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
18. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories Of Patients. Antimicrob. Agents Chemother. 55:3284-3294. http://dx.doi.org/10.1128/AAC. 01733-10.
19. Haas C, Kaufman D, Yohonn L, Forrest A, Tsuji B, Li J, He H, Nation RL. 2009. Colistin pharmacokinetics (PK) in the presence of renal and liver disease, poster 822. 38th Critical Care Congress, Nashville, TN. Crit. Care Med. 37(Suppl):A402.
20. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. http://dx.doi.org/10.1128/AAC.45.2.454-459.2001. (Pubitemid 32105280)
21. Pankuch GA, Jacobs MR, Appelbaum PC. 2003. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J. Antimicrob. Chemother. 51:443-446. http://dx.doi.org/10.1093/ jac/dkg091. (Pubitemid 36231174)
22. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62:1311-1318. http://dx.doi.org/10.1093/jac/dkn425.
23. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob. Agents Chemother. 54:2051-2062. http://dx.doi.org/10.1128/AAC.00881-09.
24. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59:473-477. http://dx.doi.org/10.1093/jac/dkl512. (Pubitemid 47073453)
25. Rao GG, Ly NS, Haas CE, Garonzik SM, Forrest AF, Bulitta JB, Kelchlin P, Li J, Nation RL, Tsuji BT. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-661.
26. Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, Tsuji BT. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53:3894-3901. http://dx.doi.org/10.1128/AAC.01585-08.
27. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. 1997. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplant. Surg. 3:628-637. http://dx.doi.org/10.1002/lt. 500030613. (Pubitemid 27498478)
28. Monarch Pharmaceuticals. 2005. Coly-Mycin M parenteral package insert. Monarch Pharmaceuticals, Bristol, TN.
29. Begic D, von Eiff C, Tsuji BT. 2009. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J. Antimicrob. Chemother. 63:977-981. http://dx.doi.org/10.1093/jac/ dkp069.
30. Giamarellou H, Poulakou G. 2009. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69:1879-1901. http://dx.doi.org/10.2165/11315690-000000000-00000.
31. Michalopoulos AS, Karatza DC. 2010. Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev. Anti Infect. Ther. 8:1009-1017. http://dx.doi.org/10.1586/eri.10.88.
32. Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin-back to basic PK/PD. Curr. Opin. Pharmacol. 11:464-469. http://dx.doi.org/10.1016/j.coph.2011.07. 004.
33. Mohamed A, Carrs O, Friberg LE. 2011. Pharmacokinetic-pharmacodynamic modeling of pre-existing and emerging resistance of Pseudomonas aeruginosa to colistin, abstr 2223. Abstr. Annu. Meet. Popul. Approach Group, Europe, Athens, Greece.
34. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56: 4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
35. Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J. 2011. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:5685-5695. http://dx.doi.org/10.1128/AAC.05298-11.
36. Koch-Weser JAN, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. 1970. Adverse effects of sodium colistimethate manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72:857-868. http://dx.doi.org/10.7326/0003-4819-72-6-857.
37. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011. http://dx.doi.org/10.1086/514732. (Pubitemid 29203530)
38. Pogue JM, Marchaim D, Kaye D, Kaye KS. 2011. Revisiting "older"antimicrobials in the era of multidrug resistance. Pharmacotherapy 31: 912-921. http://dx.doi.org/10.1592/phco.31.9.912.
39. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L. 2010. Effectiveness and safety of colistin: prospective comparative cohort study. J. Antimicrob. Chemother. 65:1019-1027. http://dx.doi.org/10.1093/jac/dkq069.
40. Falagas M, Kasiakou S. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10:R27. http://dx.doi.org/10.1186/cc3995.
41. Brown JM, Dorman DC, Roy LP. 1970. Acute renal failure due to overdosage of colistin. Med. J. Aust. 2:923-924.
42. Tsuji BT, Brown T, Parasrampuria R, Brazeau D, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Hanna D, Bulitta JB. 2012. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob. Agents Chemother. 56:3712-3719. http://dx.doi.org/10.1128/AAC.05453-11.
43. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin. Infect. Dis. 52:S513-S519. http://dx.doi.org/10.1093/cid/cir166.
44. Drusano GL, Liu W, Brown DL, Rice LB, Louie A. 2009. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus taureus. J. Infect. Dis. 199:219-226. http://dx.doi.org/10.1086/ 595739.
45. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642. http://dx.doi.org/10.1093/jac/dkm511. (Pubitemid 351321139)
46. Petrosillo N, Ioannidou E, Falagas ME. 2008. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827. http://dx.doi.org/10.1111/j.1469-0691. 2008.02061.x.
47. Zavascki A, Barth A, Fernandes J, Moro A, Goncalves A, Goldani L. 2006. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care 10:R114. http://dx.doi.org/10.1186/cc5006.